Furthermore, the presence of CXCL13+ T cells may indicate a pre-existing immune activation state within the TME, characterized by efficient antigen presentation and immune cell recruitment, thereby priming the tumor for enhanced immune surveillance and therapeutic responses. This evidence concerns the gene CXCL13 and neoplasm.